Cell line · CVCL_0028
Papers33
1 to 20 of 33
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Auranofin Potentiates Cisplatin Response in the Setting of Context-Dependent NOTCH-Associated Signaling States in Endometrial Cancer. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer-relevant paralog interplay. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DHX9 Inhibition Enhances Paclitaxel Sensitivity by Inducing Mitotic Failure in Ovarian and Endometrial Cancers. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. | Mol Syst Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| ST6GALNAC1-mediated sialylation in uterine endometrial epithelium facilitates the epithelium-embryo attachment. | J Adv Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pyroptosis-associated genes and tumor immune response in endometrial cancer. | Discov Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. | Cancer Discov | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma. | Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. | Gynecol Oncol | 2021 | Its Methods give the RRID and name the line | PubMed | |
| 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. | Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. | Cancer Cell | 2017 | Cellosaurus cites it | PubMed | |
| A Landscape of Pharmacogenomic Interactions in Cancer. | Cell | 2016 | Cellosaurus cites it | PubMed | |
| TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. | Genome Med | 2015 | Cellosaurus cites it | PubMed | |
| A resource for cell line authentication, annotation and quality control. | Nature | 2015 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0028/papers